A Multi-Institutional Phase I/II Study of Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone, and Doxil, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma.

Trial Profile

A Multi-Institutional Phase I/II Study of Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone, and Doxil, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jun 2009 Results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Millennium media release.
    • 27 May 2009 Additional lead trial investigators identified as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top